Crinetics Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Crinetics Pharmaceuticals

08/08/2025 04:08

Crinetics Pharmaceuticals Inc CRNX.OQ reported a quarterly adjusted loss of $1.23​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -94 cents.  The mean expectation of fourteen analysts for the quarter was for a loss of $1.10 per share. Wall Street expected results to range from $-1.22 to -94 cents per share.

Revenue rose 158.4% to $1.03 million from a year ago; analysts expected $129.17 thousand.

Crinetics Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.23​.

The company reported a quarterly loss of $115.64 million.

Crinetics Pharmaceuticals Inc shares had fallen by 0.8% this quarter and lost 44.2% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 0.3% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Crinetics Pharmaceuticals Inc is $72.00, about 61.3% above its last closing price of $27.88

This summary was machine generated from LSEG data August 8 at 03:07 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-1.10
-1.23
Missed
Mar. 31 2025
-0.94
-1.04
Missed
Dec. 31 2024
-0.89
-0.88
Beat
Sep. 30 2024
-0.91
-0.96
Missed